We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+24.54%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$787M
AUM Growth
+$143M
Cap. Flow
+$36.2M
Cap. Flow %
4.61%
Top 10 Hldgs %
62.09%
Holding
40
New
7
Increased
12
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$46.3M
2
ZEAL
Zealand Pharma A/S American Depositary Shares
ZEAL
+$18.8M
3
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$18.6M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$13.9M
5
KURA icon
Kura Oncology
KURA
+$12.7M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$31.2M
2
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$17.8M
3
LOXO
Loxo Oncology, Inc
LOXO
+$17.5M
4
ACHN
Achillion Pharmaceuticals
ACHN
+$16M
5
CYTK icon
Cytokinetics
CYTK
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 85.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$78.8M 10.01%
6,402,525
+342,900
+6% +$3.18M
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$70.2M 8.92%
1,007,354
-584,292
-37% -$31.2M
CCXI
3
DELISTED
ChemoCentryx, Inc.
CCXI
$56.3M 7.16%
7,587,416
-661,000
-8% -$5.49M
ANAB icon
4
AnaptysBio
ANAB
$1.63B
$48.2M 6.13%
1,379,134
-280,066
-17% -$7.55M
CNCE
5
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$46.2M 5.88%
3,135,289
+1,278,394
+69% +$18.6M
CBIO
6
Crescent Biopharma
CBIO
$555M
$45.2M 5.74%
32,299
+2,597
+9% +$3.05M
IRWD icon
7
Ironwood Pharmaceuticals
IRWD
$614M
$44.5M 5.65%
+3,367,080
New +$46.3M
CTMX icon
8
CytomX Therapeutics
CTMX
$714M
$40.5M 5.15%
2,230,898
+203,900
+10% +$3.18M
XOMA
9
DELISTED
Xoma
XOMA
$29.5M 3.75%
1,502,800
– –
BLRX
10
BioLineRX
BLRX
$11.7M
$29.1M 3.7%
43,326
+14,159
+49% +$8.79M
CTIC
11
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$27.4M 3.49%
8,596,357
– –
LOXO
12
DELISTED
Loxo Oncology, Inc
LOXO
$22M 2.79%
238,386
-225,000
-49% -$17.5M
KURA icon
13
Kura Oncology
KURA
$826M
$20.2M 2.57%
+1,353,846
New +$12.7M
OMED
14
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
– –
-4,400,289
Closed -$17.8M
ZEAL
15
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$19.2M 2.44%
+1,000,000
New +$18.8M
CYTK icon
16
Cytokinetics
CYTK
$10.9B
$18M 2.29%
1,241,021
-749,300
-38% -$10.2M
PVLA
17
Palvella Therapeutics
PVLA
$2.15B
$17.2M 2.19%
37,332
-6,317
-14% -$2.7M
RGLS
18
DELISTED
Regulus Therapeutics
RGLS
$16.2M 2.06%
107,910
+80,586
+295% +$10.1M
ITCI
19
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$15M 1.91%
+950,000
New +$13.9M
FBRX icon
20
Forte Biosciences
FBRX
$1.58B
$13.2M 1.68%
2,835
-576
-17% -$2.57M
CASC
21
DELISTED
Cascadian Therapeutics, Inc.
CASC
$12.8M 1.63%
3,133,224
– –
FSTX
22
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$11M 1.4%
163,169
+9,323
+6% +$534K
XENE icon
23
Xenon Pharmaceuticals
XENE
$6.2B
$10.6M 1.35%
3,588,830
+70,000
+2% +$217K
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$10.5M 1.33%
7,866,108
– –
ONCT
25
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$9.11M 1.16%
7,917
– –
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2017 Portfolio in Review

As of Q3 2017, BVF Inc held 40 positions worth $787M, up 22% from $644M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

BVF Inc deployed $36.2M of net new capital in Q3 2017, opening 7 new positions and adding to 12 existing holdings. Its largest new stake was Ironwood Pharmaceuticals: 3,367,080 shares worth $44.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 79% a quarter earlier.

On the sell side, the largest reduction was Blueprint Medicines, an estimated $31.2M trimmed.

  • BVF Inc's largest Q3 2017 buy was Ironwood Pharmaceuticals: 3,367,080 shares worth $44.5M.
  • BVF Inc added most to Concert Pharmaceuticals, Inc. in Q3 2017, an estimated $18.6M increase.
  • BVF Inc's biggest Q3 2017 reduction was Blueprint Medicines, cutting an estimated $31.2M.
  • BVF Inc fully exited OncoMed Pharmaceuticals, Inc. in Q3 2017, selling an estimated $17.8M.
  • BVF Inc's ten largest holdings make up 62% of its $787M portfolio in Q3 2017.
  • BVF Inc opened 7 new positions and closed 4 in Q3 2017.
  • BVF Inc's portfolio value rose 22% quarter-over-quarter to $787M.

Based on BVF Inc's 13F filing for Q3 2017, filed 14 Nov 2017.